183 filings
Page 4 of 10
8-K
1uf43f41pe
14 Apr 23
Regulation FD Disclosure
8:58am
8-K
vzh wk1vnt
4 Apr 23
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
9:34am
NT 10-K
3epop85seewlpdh6lr
31 Mar 23
Notice of late annual filing
5:12pm
8-K
jq7w 6s4c8ccf7rehfr
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
8-K
spjxa8ai16l4llz4c
24 Mar 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5:19pm
424B3
jqm18pp2
7 Mar 23
Prospectus supplement
5:03pm
EFFECT
tzaksmn61b
13 Feb 23
Notice of effectiveness
12:15am
EFFECT
m2ii37gd4v4c
9 Feb 23
Notice of effectiveness
12:15am
UPLOAD
0kfwk9zq7 o5x
8 Feb 23
Letter from SEC
12:00am
CORRESP
0gh603u17mec sd
8 Feb 23
Correspondence with SEC
12:00am
8-K
ke4huugk7vq6z5gery3
7 Feb 23
Regulation FD Disclosure
9:03am
S-3
w79tvka fuqvttsvvtc
3 Feb 23
Shelf registration
4:59pm
POS AM
zdb00hz
3 Feb 23
Prospectus update (post-effective amendment)
4:57pm
8-K
s2ufwk6ubmyhmy
27 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
4q7q 5miq1f7
10 Jan 23
Regulation FD Disclosure
9:00am
8-K
lrc6k67p
9 Jan 23
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
9:01am
8-K
iltux1lvrn3o61v nw0q
5 Jan 23
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
4:23pm
8-K
bqfo18
12 Dec 22
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
9:07am
8-K
npjwt 12lvllwz59w
21 Nov 22
Regulation FD Disclosure
4:46pm